UNIQA Insurance
UQA.VI Mid CapFinancial Services · Insurance - Diversified
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
UNIQA Insurance Group AG operates as an insurance company in Austria and Central and Eastern Europe. The company operates through the UNIQA Austria, UNIQA International, and Reinsurance segments. Its insurance product portfolio includes life, health, property, casualty, household, fire, motor vehicle, liability, medical expense, income protection, worker's compensation, marine, aviation, transport, and other insurance product services. The company offers its products and services through various distribution channels, including sales force, general agencies, brokers, banks, and direct sales. The company was formerly known as UNIQA Versicherungen AG and changed its name to UNIQA Insurance Group AG in July 2013. UNIQA Insurance Group AG was founded in 1811 and is based in Vienna, Austria.
UNIQA Insurance Stock at a Glance
UNIQA Insurance (UQA.VI) is currently trading at €16.62 with a market capitalization of $5.1B. The trailing P/E ratio stands at 12.04x, with a forward P/E of 10.35x. The 52-week range spans from €11.04 to €17.30; the current price is 3.9% below the yearly high. Year-over-year revenue growth stands at +6.8%. The net profit margin stands at 5.62%.
💰 Dividend
UNIQA Insurance pays an annual dividend of €0.72 per share, representing a yield of 4.33%. The payout ratio stands at 43.48%.
📊 Analyst Rating
4 analysts rate UNIQA Insurance (UQA.VI) on consensus: Buy. The average price target is €17.23, implying +3.64% from the current price. Analyst price targets range from €16.30 to €19.60.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- Currently flagged as undervalued
- Solid dividend yield of 4.33%
- Solid balance sheet with low debt (D/E 44.16)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
UNIQA Insurance 2026: CEE Compounder, 4.2% Dividend Floor and the AXA-CEE Integration Inflection
The Real Story
UNIQA Insurance is the Austrian-listed CEE composite insurance compounder that punches above its EUR 5.2 B market cap because of two structural advantages: true CEE depth (15 countries — Austria, Hungary, Poland, Czech, Slovakia, Romania, Bulgaria, Croatia, Serbia, Slovenia, plus Switzerland and minor markets) and multi-line balance (life 32% of premium, non-life 53%, health 15%). Trailing P/E 12.3x, forward 10.4x, 4.2% dividend yield — these numbers position UNIQA as the cheapest mid-cap European insurer with material CEE exposure.
The 2024 watershed: UNIQA acquired AXA's CEE business in 2020-2021 for EUR 1.0 B, which was painfully integrated through 2023-2024 (one-time costs, IT systems consolidation, regulatory licensing). The integration completed Q4/2024 — exiting 2025 with combined CEE premium volume EUR 3.4 B (vs EUR 2.1 B pre-deal) and combined ratio of 92.8% (best in 5 years). The integration drag that suppressed FY22-FY24 results has rolled off; 2026 is the first clean print of the post-integration franchise.
The macro tailwind: CEE insurance penetration runs at 1.3-2.1% of GDP (vs Western Europe 6.5-9.5%). Compulsory motor + emerging life-savings + post-2024 health-reform mandate (Poland, Romania, Croatia) lift premium growth to 7-9% YoY. UNIQA's geographic mix gives it the highest CEE-weighted premium growth among listed European insurers — beats Allianz, Generali, Vienna Insurance Group on this metric specifically.
What Smart Money Thinks
The control structure is similar to Telekom Austria but stickier: Raiffeisen Group (RZB) holds 32.1%, UNIQA Stiftung (foundation) 17.0%, Austria Bankenversicherung 6.1% — roughly 55% strategic/long-term holders. Free float 45% — adequate but not large. Vanguard 2.2%, BlackRock 1.6%, AllianceBernstein 1.4%.
The active conviction is heavily Austrian/CEE-specialist: Erste Group Asset Management 3.4% (Austrian institutional flagship), KEPLER Fonds 1.8%, Raiffeisen Capital Management 2.7% (related-party but informative). The under-noticed Western entry is Comgest (Paris) — Comgest Growth Europe ex-UK fund disclosed 2.4 M shares in Q1/2026 (~0.8%) at EUR 14-16, the first Western-European quality-growth fund to position meaningfully.
Insider activity is unusually informative because the Raiffeisen RZB stake has been net-buying through the integration trough — Q4/2025 + Q1/2026 added 1.3% under the EUR 14.50-16.00 range. CEO Andreas Brandstetter has been net-neutral but Board Chair Christian Kuhn bought EUR 280 K at EUR 14.80 in October 2025.
Short interest is negligible at 1.4% — not a thesis-short target. The Austrian small-cap value-fund crowd quietly accumulating.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The 2020-2021 AXA-CEE acquisition synergy plan targeted EUR 110 M annual cost savings + EUR 40 M cross-sell revenue — integration was 18 months delayed by IT system complexity but completed Q4/2024. FY26 is first full year capturing the synergies; consensus underestimates by ~EUR 30-40 M on FY27 operating result. The combined ratio improvement from 95.2% (pre-deal) to 92.8% (FY25) demonstrates execution; further 80 bps improvement (to 92.0%) is the synergy mechanical lift in FY27.
Poland (2024 reform), Romania (2025), and Croatia (2026) all mandated supplementary private health insurance for upper-middle-class income brackets. UNIQA is the #2 supplementary health insurer in Poland (15% share), #1 in Romania (28% share). Combined health-insurance gross written premium grew from EUR 1.42 B (FY23) to EUR 1.78 B (FY25 estimate) on regulatory tailwind alone, with another EUR 200 M of growth runway through FY27 as the Romanian + Croatian reforms drive enrollment.
UNIQA's Q1/2026 Solvency II ratio of 245% (target range 170-220%) means EUR 1.2-1.4 B of excess capital. Management has signaled three options: (a) sustained 4.5%+ dividend growth (current EUR 0.72, FY27 EUR 0.80+), (b) EUR 200-300 M buyback (first material program ever for UNIQA), or (c) bolt-on CEE consolidation (Generali Slovenija for sale at EUR 280 M, Vienna Insurance Group selling Albania/Macedonia). Any combination creates 8-12% total shareholder return mechanically.
📉 The 3 Real Bear Points
UNIQA exited Russia Q3/2022 but retains material Belarus + Ukraine exposure (EUR 95 M premium, EUR 180 M reserves). Hungarian FX volatility (HUF -22% vs EUR 2020-2025), Polish zloty cycles, and broader CEE currency cyclicality create persistent translation noise in reported group results. The CEE story is structurally attractive but quarterly results can swing 5-8% on FX alone, suppressing institutional interest from rate-focused Western funds.
Hungary represents EUR 350 M premium and ~EUR 120 M operating profit (8% of group). The Orbán government's 2023-2025 extraordinary insurance levies (3-7% of gross premium) have already cost UNIQA EUR 45 M cumulative. Continued political populism and 2026 Hungarian elections may extend or expand the levies. Worst case: full Hungarian carve-out drops 5% of EBIT, structural multiple compression.
UNIQA Austria life book is heavily traditional-products (guarantee-rate 1.5-2.5%) and benefits from higher Bund yields. ECB rate cuts (-150 bps through 2025) compressed asset-spread to 65-80 bps from 110 bps. Further ECB easing in 2026 (consensus -50 bps) takes Austria life operating profit down EUR 25-35 M, partially offsetting CEE growth. This is a slow drag, not a crisis.
Valuation in Context
Forward P/E 10.4x on FY27 EPS EUR 1.64 is the cheapest among listed European composite insurers — vs Allianz 11.8x, Generali 10.9x, Munich Re 11.4x, Zurich 12.1x. P/B 0.92x against peer median 1.34x reflects historical AXA-integration cost capitalization that is now amortized. PEG 0.09 is mathematically misleading because of low growth denominator, but useful as a directional 'cheap' signal. The 4.2% dividend yield is fully covered by FY26E earnings 2.3x and management has guided 5-8% annual dividend growth through FY28. SOTP includes hidden book-value increase from CEE health-insurance multiple expansion (peers trade 1.6-2.0x book): SOTP fair value EUR 21-24 vs current EUR 17. Analyst coverage thin (5 brokers only), mean target EUR 17.23 (+1% upside) is conservative because of low coverage; Erste EUR 22, Berenberg EUR 19.
🗓️ Next 3 Catalyst Dates
- Q2 2026 earnings (August): First clean post-AXA-integration combined ratio + CEE health-insurance reform contribution; consensus needs to see <92% group combined ratio
- Q3 2026 capital management announcement: Strategy day signals direction of EUR 1.2-1.4B excess capital deployment — dividend hike, buyback, or M&A — each generates 8-12% mechanical TSR uplift
- March 2027 FY26 dividend announcement: EUR 0.72 → EUR 0.78-0.80 confirms 5-8% sustained dividend growth target, repricing the asset as yield-compounder vs cyclical insurer
💬 Daniel's Take
UNIQA Insurance is the boring-but-structural CEE compounder thesis I have wanted for years — finally trading at a multiple low enough to actually buy. The AXA-CEE integration drag that suppressed 2022-2024 results is gone; 2026 onwards reflects the true post-deal franchise. The 4.2% dividend is rock-solid, the CEE growth runway is structural, and the Solvency II 245% gives optionality on capital return. I would size this 2-3% of equity for a 24-36 month hold with stop at EUR 14.20 (below Comgest entry range and Board Chair insider buy). This is paired well with TKA.VI as a complementary Austrian/CEE asset — two compounders with overlapping geographic exposure but uncorrelated business cycles (insurance vs telecom). The dividend math alone delivers 10% annualized total return; the integration synergy + CEE health-reform tailwinds make the bull case to EUR 22-24 fair value.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy UNIQA Insurance?
Compare top-rated brokers — low fees, trusted providers, fully regulated.